NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$46.94|
|52 Week High||US$35.74|
|52 Week Low||US$61.57|
|1 Month Change||-3.20%|
|3 Month Change||0.95%|
|1 Year Change||29.81%|
|3 Year Change||212.52%|
|5 Year Change||481.30%|
|Change since IPO||1,705.39%|
Recent News & Updates
|NEO||US Life Sciences||US Market|
Return vs Industry: NEO underperformed the US Life Sciences industry which returned 56.4% over the past year.
Return vs Market: NEO underperformed the US Market which returned 35.3% over the past year.
Stable Share Price: NEO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: NEO's weekly volatility (5%) has been stable over the past year.
About the Company
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates in two segments, Clinical Services and Pharma Services. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains.
NeoGenomics Fundamentals Summary
|NEO fundamental statistics|
Is NEO overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|NEO income statement (TTM)|
|Cost of Revenue||US$276.84m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.58|
|Net Profit Margin||14.68%|
How did NEO perform over the long term?See historical performance and comparison
Is NeoGenomics undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate NEO's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate NEO's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: NEO is poor value based on its PE Ratio (80.3x) compared to the US Life Sciences industry average (53.1x).
PE vs Market: NEO is poor value based on its PE Ratio (80.3x) compared to the US market (17.9x).
Price to Earnings Growth Ratio
PEG Ratio: NEO's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: NEO is good value based on its PB Ratio (5x) compared to the US Life Sciences industry average (6.1x).
How is NeoGenomics forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NEO's earnings are forecast to decline over the next 3 years (-81.8% per year).
Earnings vs Market: NEO's earnings are forecast to decline over the next 3 years (-81.8% per year).
High Growth Earnings: NEO's earnings are forecast to decline over the next 3 years.
Revenue vs Market: NEO's revenue (13.8% per year) is forecast to grow faster than the US market (9.8% per year).
High Growth Revenue: NEO's revenue (13.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NEO is forecast to be unprofitable in 3 years.
How has NeoGenomics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NEO has a large one-off loss of $15.9M impacting its June 30 2021 financial results.
Growing Profit Margin: NEO became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: NEO has become profitable over the past 5 years, growing earnings by 64% per year.
Accelerating Growth: NEO has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: NEO has become profitable in the last year, making it difficult to compare its past year earnings growth to the Life Sciences industry (56.9%).
Return on Equity
High ROE: NEO's Return on Equity (6.2%) is considered low.
How is NeoGenomics's financial position?
Financial Position Analysis
Short Term Liabilities: NEO's short term assets ($721.8M) exceed its short term liabilities ($99.1M).
Long Term Liabilities: NEO's short term assets ($721.8M) exceed its long term liabilities ($648.8M).
Debt to Equity History and Analysis
Debt Level: NEO's debt to equity ratio (46.5%) is considered high.
Reducing Debt: NEO's debt to equity ratio has increased from 21.7% to 46.5% over the past 5 years.
Debt Coverage: NEO's debt is not well covered by operating cash flow (1.4%).
Interest Coverage: Insufficient data to determine if NEO's interest payments on its debt are well covered by EBIT.
What is NeoGenomics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NEO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NEO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NEO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NEO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NEO's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mark Mallon (58 yo)
Mr. Mark W. Mallon serves as Chief Executive Officer and Director at NeoGenomics Laboratories, Inc. since April 19, 2021. He serves as Chief Executive Officer and Director at NeoGenomics, Inc. since April...
Experienced Management: NEO's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Experienced Board: NEO's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.4%.
NeoGenomics, Inc.'s employee growth, exchange listings and data sources
- Name: NeoGenomics, Inc.
- Ticker: NEO
- Exchange: NasdaqCM
- Founded: 2001
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$5.772b
- Shares outstanding: 122.97m
- Website: https://www.neogenomics.com
Number of Employees
- NeoGenomics, Inc.
- 12701 Commonwealth Drive
- Suite 9
- Fort Myers
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/27 23:00|
|End of Day Share Price||2021/09/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.